“双一流”建设下我国药学学科的科研竞争力水平评价——来自48家高校院所的实证

Scientific Research Competitiveness Level Evaluation of Pharmacy Discipline in China Under the"Double First-class"Construction:Empirical Evidence from 48 Universities and Institutes

为丰富从获取科研基金角度分析我国高校院所药学科研竞争力的研究,基于2005—2019年间国家自然科学基金(NSFC)在药物学、药理学领域有关资助数据,从基金项目经费、基金项目负责人数量等维度构建改进的药学学科科研竞争力指数(PSCI),以国内设有药学一级学科博士学位授权点的48家高校院所为实证对象,分析其药学学科科研资助情况、科研竞争力及变化趋势。结果显示:NSFC在药物学、药理学领域的资助以面上项目和青年科学基金项目为主,资助项目数量和经费均呈现出先快速增长后平稳发展的态势,表明我国药物学与药理学领域基础研究水平已达一定高度;药学学科科研竞争力强的单位主要集中在东部沿海和北部沿海综合经济区;高校院所药学学科科研竞争力位次呈固化趋势,科研资源聚集现象显著。

Based on the data of projects funded by the National Natural Science Foundation of China(NSFC)in the fields of materia medica and pharmacology from 2005 to 2019,this paper aims to enrich the research on pharmaceutical research competitiveness of Chinese institutes from the perspective of obtaining scientific research funds.Improved pharmaceutical scientific research competitiveness index(PSCI)from the dimensions of obtained scientific research funds and fund project leader number is constructed,and 48 first-level pharmacy doctoral degree authorization units in China are taken as the research objects to analyze the current situation of pharmaceutical research funding,scientific research competitiveness and changing trend.The results show that,NSFC's funding in the fields of materia medica and pharmacology is mainly general projects and youth science fund projects,and the funded projects number and expenditure presented a trend of rapid growth first and then stable development,indicating that the basic research level in the field of pharmacology and pharmacology in China has reached a certain height;the units with strong pharmaceutical scientific research competitiveness are mainly concentrated in the eastern and northern coastal economic zones;and the ranking of scientific research competitiveness of pharmaceutical disciplines among colleges and universities shows a consistent trend,and the phenomenon of scientific research resources aggregation is remarkable.